: Uterine myomas and endometriosis are painful, benign hormone-dependent diseases affecting women of reproductive age. Substantial efforts have been made to develop innovative medical options for treating these gynecologic diseases. Elagolix and relugolix have been approved in some countries for treating endometriosis and uterine myomas, respectively; however, linzagolix (OBE 2109, KLH 2109) is a new oral gonadotropin-releasing hormone (GnRH) antagonist in phase II-III trials. Treatment options for women with contraindications for certain hormonal therapies or who refuse particular options, are the driving force behind the development of new drugs in this area.
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas
D'Alterio, Maurizio Nicola;
2021-01-01
Abstract
: Uterine myomas and endometriosis are painful, benign hormone-dependent diseases affecting women of reproductive age. Substantial efforts have been made to develop innovative medical options for treating these gynecologic diseases. Elagolix and relugolix have been approved in some countries for treating endometriosis and uterine myomas, respectively; however, linzagolix (OBE 2109, KLH 2109) is a new oral gonadotropin-releasing hormone (GnRH) antagonist in phase II-III trials. Treatment options for women with contraindications for certain hormonal therapies or who refuse particular options, are the driving force behind the development of new drugs in this area.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
